UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
CYTORI THERAPEUTICS, INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
23283K105
(CUSIP Number)
DECEMBER 31, 2006
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS
FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB
CONTROL NUMBER.
SEC 1745 (12-02)
---------------------------------------- -------------------------------------- --------------------------------------
CUSIP No. 23283K105 13G Page 2 of 6 Pages
---------------------------------------- -------------------------------------- --------------------------------------
--------- ------------------------------------------------------------------------------------------------------------
1.
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
NEIL GAGNON
--------- ------------------------------------------------------------------------------------------------------------
--------- ------------------------------------------------------------------------------------------------------------
2.
CHECK THE APPROPRIATE BOX IF A GROUP* (a)
(b) |X|
--------- ------------------------------------------------------------------------------------------------------------
--------- ------------------------------------------------------------------------------------------------------------
3. SEC USE ONLY
--------- ------------------------------------------------------------------------------------------------------------
--------- ------------------------------------------------------------------------------------------------------------
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
UNITED STATES OF AMERICA
--------- ------------------------------------------------------------------------------------------------------------
------------------- ----- --------------------------------------------- ----------------------------------------------
NUMBER OF 5.
SHARES SOLE VOTING POWER 1,000,122
------------------- ----- --------------------------------------------- ----------------------------------------------
------------------- ----- --------------------------------------------- ----------------------------------------------
BENEFICIALLY 6.
OWNED BY SHARED VOTING POWER 446,846
------------------- ----- --------------------------------------------- ----------------------------------------------
------------------- ----- --------------------------------------------- ----------------------------------------------
EACH 7.
REPORTING SOLE DISPOSITIVE POWER 940,521
------------------- ----- --------------------------------------------- ----------------------------------------------
------------------- ----- --------------------------------------------- ----------------------------------------------
PERSON WITH: 8.
SHARED DISPOSTIVE POWER 1,351,069
------------------- ----- --------------------------------------------- ----------------------------------------------
--------- ---------------------------------------------------------------------------- -------------------------------
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,291,590
--------- ---------------------------------------------------------------------------- -------------------------------
--------- ------------------------------------------------------------------------------------------------------------
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
--------- ------------------------------------------------------------------------------------------------------------
--------- ---------------------------------------------------------------------------- -------------------------------
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 12.24%
--------- ---------------------------------------------------------------------------- -------------------------------
--------- ---------------------------------------------------------------------------- -------------------------------
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN
--------- ---------------------------------------------------------------------------- -------------------------------
---------------------------------------- -------------------------------------- ----------------------------------------
CUSIP No. 23283K105 13G Page 3 of 6 Pages
---------------------------------------- -------------------------------------- ----------------------------------------
ITEM 1.
(a) Name of Issuer: CYTORI THERAPEUTICS, INC.
(b) Address of Issuer's Principal Executive Offices:
3020 CALLAN ROAD
SAN DIEGO, CA 92121
ITEM 2.
(a) Name of Person Filing: NEIL GAGNON
(b) Address of Principal Business Office or, if none, Residence:
1370 AVE. OF THE AMERICAS, SUITE 2400
NEW YORK, NY 10019
(c) Citizenship: US
(d) Title of Class of Securities: COMMON STOCK, PAR VALUE $0.001 PER SHARE
(e) CUSIP Number: 23283K105
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.SS.240.13D-1(B) OR
240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C.
78o).
(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15
U.S.C. 78c).
(d) [ ] Investment company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C 80a-8).
(e) [ ] An investment adviser in accordance with
ss.240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with
ss.240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with ss.
240.13d-1(b)(1)(ii)(G);
(h) [ ] A savings associations as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment Company
Act of 1940 (15 U.S.C. 80a-3);
(j) [ ] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
---------------------------------------- -------------------------------------- ----------------------------------------
CUSIP No. 23283K105 13G Page 4 of 6 Pages
---------------------------------------- -------------------------------------- ----------------------------------------
ITEM 4. OWNERSHIP.
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: As of December 31, 2006, Neil Gagnon beneficially owned 2,291,590 shares
of Common Stock of Cytori Therapeutics, Inc., which amount includes (i)
489,411 shares beneficially owned by Mr. Gagnon over which he has sole
voting power and sole dispositive power; (ii) 55,036 shares beneficially
owned by Mr. Gagnon over which he has sole voting power and shared
dispositive power; (iii) 282,185 shares beneficially owned by Lois
Gagnon, Mr. Gagnon's wife, over which he has shared voting power and
shared dispositive power; (iv) 2,955 shares beneficially owed by Mr.
Gagnon and Mrs. Gagnon as Joint Tenants with Rights of Survivorship, over
which he has shared voting power and shared dispositive power; (v) 63,446
shares held by the Lois E. and Neil E. Gagnon Foundation (the
"Foundation"), of which Mr. Gagnon is a trustee and over which he has
shared voting power and shared dispositive power; (vi) 98,260 shares held
by the Gagnon Family Limited Partnership (the "Partnership") of which
Mr. Gagnon is a partner and over which he has shared voting power and
shared dispositive power; (vii) 80,660 shares held by the Gagnon
Grandchildren Trust (the "Trust") over which Mr. Gagnon has shared
dispositive power but no voting power; (viii) 447,695 shares held by four
hedge funds (collectively, the "Funds"), of which Mr. Gagnon is either
the principal executive officer of the manager or the managing member of
a member of the general partner or the managing member and over which he
has sole dispositive power and sole voting power; (ix) 3,415 shares held
by the Gagnon Securities LLC Profit Sharing Plan and Trust (the "Plan")
of which Mr. Gagnon is a Trustee and over which Mr. Gagnon has sole
voting power and sole dispositive power; (x) 4,565 shares held by the
Plan over which Mr. Gagnon has sole voting power and shared dispositive
power; and (xi) 763,962 shares held for certain customers of Gagnon
Securities LLC, of which Mr. Gagnon is the managing member and the principal
owner and over which he has shared dispositive but no voting power.
(b) Percent of class: 12.24% beneficially owned by Mr. Gagnon. Calculation of percentage of
beneficial ownership is based on 18,722,735 shares of Issuer's Common
Stock outstanding as of November 14, 2006, as reported by the Issuer on
its Form 10-Q for the period ended September 30, 2006.
---------------------------------------- -------------------------------------- ----------------------------------------
CUSIP No. 23283K105 13G Page 5 of 6 Pages
---------------------------------------- -------------------------------------- ----------------------------------------
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: 1,000,122
(ii) Shared power to vote or to direct the vote: 446,846
(iii) Sole power to dispose or to direct the disposition of: 940,521
(iv) Shared power to dispose or to direct the disposition of: 1,351,069
ITEM 5-9 Not Applicable
Filing of this statement by Mr. Gagnon shall not bee deemed an admission that he
beneficially owns the securities reported herein as held in customer accounts at
Gagnon Securities LLC or by the Foundation, the Partnership, the Trust, the
Funds or the Plan. Mr. Gagnon expressly disclaims beneficial ownership of all
securities held in such customer accounts or by the Foundation, the Partnership,
the Trust, the Funds or Plan. No single client's interest as reported in the
customer accounts at Gagnon Securities LLC exceeds 5% of the outstanding Common
Stock of the Issuer.
ITEM 10. CERTIFICATION
(a) The following certification shall be included if the statement is filed pursuant to ss.240.13d-1(b):
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above
were acquired and are held in the ordinary course of
business and were not acquired and are not held for the
purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not
acquired and are not held in connection with or as a
participant in any transaction having that purpose or
effect. [X]
---------------------------------------- -------------------------------------- --------------------------------------
CUSIP No. 23283K105 13G Page 6 of 6 Pages
---------------------------------------- -------------------------------------- --------------------------------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
FEBRUARY 5, 2007
----------------
Date
/S/ NEIL GAGNON
---------------
Signature
NEIL GAGNON
Name/Title
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is signed
on behalf of a person by his authorized representative other than an executive
officer or general partner of the filing person, evidence of the
representative's authority to sign on behalf of such person shall be filed with
the statement, provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or
printed beneath his signature.
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. SEE ss.240.13d-7 for other
parties for whom copies are to be sent.
ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001)